Clinical Application of Mg Based Biodegradable Material for Fracture Fixation in the Adult Skeleton

NCT ID: NCT05245981

Last Updated: 2023-01-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-07-09
• Study Completion Date: 2023-01-17

Brief Summary

This study is a prospective, non-randomized trial for the treatment of fractures of the medial malleolus using lean, bioabsorbable, rare-earth element (REE) free, magnesium (Mg)-based biodegradable screws in the adult skeleton.

A total of 20 patients with isolated, bimalleolar, or trimalleolar ankle fractures were recruited between July 2018 and October 2019. Fracture reduction was achieved through bioabsorbable Mg-based screws composed of pure Mg alloyed with zinc (Zn) and calcium (Ca) (0.45 wt% Zn and 0.45 wt% Ca; ZX00). Visual analogue scale (VAS) and the presence of complications (adverse events) during follow-up (12 weeks) were used to evaluate the clinical outcomes. The functional outcomes were analyzed through the range of motion (ROM) of the ankle joint and the American Orthopaedic Foot and Ankle Society (AOFAS) score. Fracture reduction and gas formation were assessed using several plane radiographs.

Detailed Description

The pilot study was designed as a prospective, nonrandomized trial for the treatment of displaced fractures of the medial malleolus with a lean, REE-free, Mg-based biodegradable implant in the adult skeleton. The trial was conducted according to the Good Clinical Practice (ISO 14155:2011) standard and the Declaration of Helsinki.The study was performed at the Department of Orthopaedics and Trauma at the Medical University of Graz and approved by the ethics committee (28 - 071 ex 15/16). A total of 20 subjects were recruited and operated on by three experienced surgeons in the centre between July 2018 and October 2019. Inclusion focused on adults aged between 18 and 65 years presenting with a displaced isolated medial malleolus fracture, a bimalleolar ankle fracture, or a trimalleolar ankle fracture. Fracture displacement was defined as diastasis of the fracture in any direction of 2 mm or more. Exclusion criteria were pathological fractures, underlying diseases (particularly bone diseases, kidney diseases, diabetes mellitus), polytraumatized patients, and pregnant or breastfeeding women.Written informed consent was obtained from each patient before the surgery. All radiological data were stored in a picture archiving and communication system (PACS). Fractures were classified according to the Herscovici system.25

Description of the bioresorbable device used: Ultra-high pure Mg (99.999%) was alloyed with Zn and Ca (0.45 wt% Zn and 0.45 wt% Ca) at 750°C under a protective gas atmosphere. Prepared screws had a length of 40 mm and a diameter of 3.5 mm. Implants were threaded at the distal part for use as traction screws.

Surgery: All patients were operated in a supine position. In case of a bimalleolar or trimalleolar fracture, the fibular and the dorsal tibial fragments were treated before the medial malleolus. Subsequently, two parallel Kirschner wires perpendicular to the medial malleolar fracture line were positioned with fluoroscopic control. A cannulated drill bit with 2.7 mm width was used for preparing the hole. Subsequently, one wire was removed and the ZX00 compression screw was inserted into the hole. Final fixation of the fracture was achieved with the second bioabsorbable Mg screw after removal of the second wire. The insertion torque of the screws was limited at a force of 1.5 newton metre with a torque handle. In all patients, no additional implants other than the Mg screws were used for the fixation of the medial malleolus. Patients with bimalleolar fractures and trimalleolar fractures were fixed with titanium plates and screws. Moreover, patients were immobilized with an under-knee plaster cast four to six weeks postoperatively and encouraged to attempt full weight-bearing as tolerated. Ankle movement exercises were started immediately after removal of the plaster.

Assessments and measurements: For each subject, the study consisted of assessments conducted preoperatively, immediately after operation and postoperative followup visits. During follow-up, complications including vital signs, erythema, swelling, pain, secretions, wound healing disorders, wound infections, or implant infections were recorded. Pain was assessed using visual analogue scale (VAS). Blood analysis and detection of Ca and Mg were recorded. Functional outcomes were evaluated through range of motion (ROM) in dorsal and plantar flexion. Additionally, the American Orthopaedic Foot and Ankle Society (AOFAS) score was performed after three months. Anteroposterior and lateral ankle radiographs (X-rays) were used to evaluate the fracture union and loss of reduction during follow-up. Postoperative radiograph evaluation was performed by two independent radiologists.

The study was registered retrospectively on Clinicaltrials.gov.

Conditions

Fracture of Medial Malleolus

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

BRI.MAG 2

Patients presenting with dislocated isolated or combined fracture of the medialis malleolus are eligible to receive the investigational device.

Group Type: EXPERIMENTAL

BRI.MAG 2

Intervention Type: DEVICE

Patients presenting with dislocated isolated or combined fracture of the medialis malleolus, will be screened for eligibility. Every effort will be made to ensure eligibility of the patients prior to enrollment. 20 patients will be recruited for the study.

Interventions

BRI.MAG 2

Patients presenting with dislocated isolated or combined fracture of the medialis malleolus, will be screened for eligibility. Every effort will be made to ensure eligibility of the patients prior to enrollment. 20 patients will be recruited for the study.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Patients with a dislocated fracture of the medial malleolus. Dislocation is defined as diastasis of the fracture in any direction of 2 mm or more.
• Otherwise healthy patients (women and men) in the age-group 18 to 65 years
• Subject has been informed of the nature of the study, agrees to participate and signs the approved consent forms. Included in this procedure is the standard information about the operation procedure.
• Subject is able and willing to comply with all assessments in the study
• Female subject with child-bearing potential perform a pregnancy test

Exclusion Criteria

• pathological fractures (f.e. bone cyst)
• underlying diseases (particularly bone diseases, kidney diseases, diabetes mellitus)
• poly-traumatized patient
• multiple fractures at the same extremity
• pregnant or breastfeeding women
• inability or unwillingness to give informed consent

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Laura Bassi Fond; AUVA

UNKNOWN

Sponsor Role: collaborator

Medical University of Graz

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Franz Josef Seibert, Prof.Dr.

Role: PRINCIPAL_INVESTIGATOR

Medical University of Graz, Departement of orthopaedics and traumatology

Locations

Medical University of Graz

Graz, Styria, Austria

Countries

Austria

Other Identifiers

BRI.MAG 2

Identifier Type: -

Identifier Source: org_study_id